Determination of SNX-2112, a selective Hsp90 inhibitor, in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 4, 2010, Pages 1048-1052

  Zhai, Qian Qian ^a,b   Gong, Guo Qin ^a   Luo, Yong ^a   Wang, Qing Duan ^c   Xia, Min ^a   Xing, Guo Wen ^d   Li, Yi Cheng ^a   Jiang, Jin Hua ^c   Liu, Zhong ^a   Liu, Qiu Ying ^a   Wang, Yi Fei ^a  

^a JINAN UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c Henan Academy of Medical and Pharmaceutical Sciences   (China)

^d BEIJING NORMAL UNIVERSITY   (China)

Author keywords

HPLC; Pharmacokinetics; Rat plasma; SNX 2112; UV detector

Indexed keywords

4 (6,6 DIMETHYL 4 O 3 TRIFLUOROMETHYL 4,5,6,7 TETRAHYDRO 1 INDOLEYL) 2 [1 (4 HYDROXYCYCLOHEXANE)AMINO]BENZAMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; SNX 2112; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77955588946     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.06.031     Document Type: Article

References (14)

1. Stangl K., Günther C., Frank T., Silke Meiners M., Röpke T., Stelter L., Moobed M., Baumann G., Kloetzel P.M., Stangl V. Inhibition of the ubiquitin-proteosome path way induces differential heat shock protein response in cardiomyocytes and renders early cardiac protection. Biochem. Biophys. Res. Commun. 2002, 291:542-549.
2. Pearl L.H., Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. 2001, 59:157-186.
3. Pratt W.B. The Hsp902 based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp. Biol. Med. 1998, 217:420-434.
4. Kwon H.J., Yoshida M., Fukui Y., Horinouchi S., Beppu T. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 1992, 52:6926-6930.
5. Agatsuma T., Ogawa H., Akasaka K., Asai A., Yamashita Y., Mizukami T., Akinaga S., Saitoh Y. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg. Med. Chem. 2002, 10:3445-3454.
6. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000, 11:355-360.
7. Chiosis G., Huezo H., Rosen N., Mimnaugh E., Whitesell L., Neckers L. 17-AAG: low target binding affinity and potent cell activity-finding an explanation. Mol. Cancer Ther. 2003, 2:123-129.
8. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC330507) bymurine and human hepatic preparations. Cancer Res. 1998, 58:2385-2396.
9. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42:273-279.
10. Barta T.E., Veal J.M., Rice J.W., Partridge J.M., Fadden R.P., Ma W., Jenks M., Geng L., Hanson G.J., Huang K.H., Barabasz A.F., Foley B.E., Otto J., Hall S.E. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg. Med. Chem. Lett. 2008, 18:3517-3521.
11. Chandarlapaty S., Sawai A., Ye Q., Scott A., Silinski M., Huang K., Fadden P., Partdrige J., Hall S., Steed P., Norton L., Rosen N., Solit1 D.B. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 2008, 14:240-248.
12. Okawa Y., Hideshima T., Steed P., Vallet S., Hall S., Huang K., Rice J., Barabasz A., Foley B., Ikeda H., Raje N., Kiziltepe T., Yasui H., Enatsu S., Anderson K.C. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
13. Jin L., Xiao C.L., Lu C.H., Xia M., Xing G.W., Xiong S., Liu Q.Y., Liu H., Li Y.C., Ge F., Wang Q.D., He Q.Y., Wang Y.F. Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett. 2009, 583:1859-1866.
14. Bryson J.C., Infante J.R., Ramanathan R.K., Jones S.F., Von Hoff D.D., Burris H.A. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. J. Clin. Oncol. 2008, 26:14613.